Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.
It is well established that the gp120 V3 loop of T-cell-line-adapted human immunodeficiency virus type 1 (HIV-1) binds both cell-associated and soluble polyanions. Virus infectivity is increased by interactions between HIV-1 and heparan sulfate proteoglycans on some cell types, and soluble polyanions such as heparin and dextran sulfate neutralize HIV-1 in vitro. However, the analysis of gp120-polyanion interactions has been limited to T-cell-line-adapted, CXCR4-using virus and virus-derived gp120, and the polyanion binding ability of gp120 regions other than the V3 loop has not been addressed. Here we demonstrate by monoclonal-antibody inhibition, labeled heparin binding, and surface plasmon resonance studies that a second site, most probably corresponding to the newly defined, highly conserved coreceptor binding region on gp120, forms part of the polyanion binding surface. Consistent with the binding of polyanions to the coreceptor binding surface, dextran sulfate interfered with the gp120-CXCR4 association while having no detectable effect on the gp120-CD4 interaction. The interaction between polyanions and X4 or R5X4 gp120 was readily detectable, whereas weak or undetectable binding was observed with R5 gp120. Analysis of mutated forms of X4 gp120 demonstrated that the V3 loop is the major determinant for polyanion binding whereas other regions, including the V1/V2 loop structure and the NH(2) and COOH termini, exert a more subtle influence. A molecular model of the electrostatic potential of the conserved coreceptor binding region confirmed that it is basic but that the overall charge on this surface is dominated by the V3 loop. These results demonstrate a selective interaction of gp120 with polyanions and suggest that the conserved coreceptor binding surface may present a novel and conserved target for therapeutic intervention.
Moulard
M
M
Centre d'Immunologie de Marseille-Luminy, 13288 Marseille Cedex 9, France.
Lortat-Jacob
H
H
Mondor
I
I
Roca
G
G
Wyatt
R
R
Sodroski
J
J
Zhao
L
L
Olson
W
W
Kwong
P D
PD
Sattentau
Q J
QJ
D000911:Antibodies, Monoclonal / Q000378:metabolism; D001665:Binding Sites; D015704:CD4 Antigens / Q000378:metabolism; D018985:Epitopes, B-Lymphocyte / Q000378:metabolism; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000378:metabolism*; D015497:HIV-1 / Q000378:metabolism*; D006493:Heparin / Q000378:metabolism; D006801:Humans; D016296:Mutagenesis; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism*; D000071228:Polyelectrolytes; D011108:Polymers / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism; D055672:Static Electricity; D013462:Sulfur Radioisotopes; D020349:Surface Plasmon Resonance; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D018985:Epitopes, B-Lymphocyte; D015699:HIV Envelope Protein gp120; D006493:Heparin; D010446:Peptide Fragments; D000071228:Polyelectrolytes; D011108:Polymers; D019718:Receptors, CXCR4; D013462:Sulfur Radioisotopes; C059762:HIV envelope protein gp120 (305-321)